Yttrium aluminum garnet laser capsulotomy after cataract surgery is tied to an increased risk for the progression of ...
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial ...
Advancing wet AMD & diabetic eye trials, strong cash runway to 2028, and aiming for a market-leading superiority label.
A new national survey from the Canadian Ophthalmological Society (COS) reveals a concerning awareness gap regarding diabetes-related vision loss, with only one in four Canadians (25%) familiar with ...
AI-powered retinal imaging closes healthcare gaps, enables earlier intervention, and reveals new insights into systemic ...
Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved tar ...
Seven public events have been planned by the Bermuda Diabetes Association for November to help spread awareness and build ...
A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic ...
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027Together with SOL-1, these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback